UroGen receives rights to Zalifrelimab for intravesical treatment of urinary tract cancers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

UroGen Pharma paid $10 million to Agenus Inc. for access to zalifrelimab (AGEN1884, anti-CTLA-4 antibody) for use with sustained release technology for intravesical delivery in patients with urinary tract cancers.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login